BioNumerik's novel chemoprotecting agent BNP7787 appears to protect against taxane and platinum associated neurotoxicity
Novel class of highly lipophilic camptothecins, known as Karenitecins, demonstrates oral antitumor activity and high potency
Philadelphia, PA; April 12, 1999 -- BioNumerik Pharmaceuticals, Inc. this week is presenting new data on two novel supercomputer-engineered small molecule agents designed to help address common and important unmet needs in cancer therapy. BioNumerik's BNP7787 is a novel chemoprotecting agent designed to increase the therapeutic index and protect against the common toxicities of widely used anticancer drugs, including taxane and platinum based agents.
BioNumerik's karenitecin is a novel silicon-containing anticancer compound that has demonstrated potent antitumor activity at concentrations as low as parts per trillion in laboratory testing with human cancer cell lines and in animals bearing human tumors. Karenitecin is in the drug class known as camptothecins and has been designed to avoid problems with oral bioavailability, unfavorable metabolism, toxicity and drug resistance that have been associated with other camptothecins.
BioNumerik is presenting new data from animal and laboratory studies that further confirm the ability of BNP7787 to protect against drug-induced nerve damage (or neurotoxicity) that is associated with administration of taxane and platinum drugs, two widely used classes of anticancer compounds. In addition, BioNumerik is reporting additional confirmatory laboratory evidence that BNP7787 does not reduce the antitumor effects of taxanes, platinum or other cytotoxic drugs in human cancer cell lines or in implanted tumors in animals.
Taxane and platinum drugs are administered in the treatment of a variety of
common cancers including breast, lung, ovarian and many other tumors. Some of
the most widely used taxane
Contact: Amy Flood
415-677-4455 x. 211